Sutro inks $390M royalty financing deal with Blackstone; Clinical hold on Pharvaris' HAE drug lifted
Sutro Biopharma is landing a $140 million upfront in exchange for handing off its royalty in potential future sales of Vaxcyte’s candidates.
The deal, …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
